| 1 | A BOILED‐Egg To Predict Gastrointestinal Absorption and Brain Penetration of Small Molecules | ChemMedChem | 2016 | 1,914 |
| 2 | Topical Delivery of Silver Nanoparticles Promotes Wound Healing | ChemMedChem | 2007 | 693 |
| 3 | Discovery of Selective Irreversible Inhibitors for Bruton’s Tyrosine Kinase | ChemMedChem | 2007 | 530 |
| 4 | Lessons Learnt from Assembling Screening Libraries for Drug Discovery for Neglected Diseases | ChemMedChem | 2008 | 506 |
| 5 | G‐Quadruplexes: Targets in Anticancer Drug Design | ChemMedChem | 2008 | 436 |
| 6 | Revealing Atropisomer Axial Chirality in Drug Discovery | ChemMedChem | 2011 | 412 |
| 7 | Carboxylic Acid (Bio)Isosteres in Drug Design | ChemMedChem | 2013 | 407 |
| 8 | Predicting and Tuning Physicochemical Properties in Lead Optimization: Amine Basicities | ChemMedChem | 2007 | 398 |
| 9 | On the Art of Compiling and Using 'Drug‐Like' Chemical Fragment Spaces | ChemMedChem | 2008 | 391 |
| 10 | Prodrug Strategies in Anticancer Chemotherapy | ChemMedChem | 2008 | 385 |
| 11 | Modern Subunit Vaccines: Development, Components, and Research Opportunities | ChemMedChem | 2013 | 357 |
| 12 | Ionic Liquids as Active Pharmaceutical Ingredients | ChemMedChem | 2011 | 304 |
| 13 | Quaternary Ammonium Salts and Their Antimicrobial Potential: Targets or Nonspecific Interactions? | ChemMedChem | 2012 | 298 |
| 14 | Silver Nanoparticles Mediate Differential Responses in Keratinocytes and Fibroblasts during Skin Wound Healing | ChemMedChem | 2010 | 258 |
| 15 | Fueling Open‐Source Drug Discovery: 177 Small‐Molecule Leads against Tuberculosis | ChemMedChem | 2013 | 250 |
| 16 | Thiadiazole—a Promising Structure in Medicinal Chemistry | ChemMedChem | 2013 | 248 |
| 17 | Cellular Uptake, Cytotoxicity, and Metabolic Profiling of Human Cancer Cells Treated with Ruthenium(II) Polypyridyl Complexes [Ru(bpy)2(NN)]Cl2 with NN=bpy, phen, dpq, dppz, and dppn | ChemMedChem | 2008 | 242 |
| 18 | The 7 TM G‐Protein‐Coupled Receptor Target Family | ChemMedChem | 2006 | 233 |
| 19 | Drug Development and Medicinal Chemistry Efforts toward SARS‐Coronavirus and Covid‐19 Therapeutics | ChemMedChem | 2020 | 229 |
| 20 | Analysis of Pharmacology Data and the Prediction of Adverse Drug Reactions and Off-Target Effects from Chemical Structure | ChemMedChem | 2007 | 225 |
| 21 | Prediction of ADMET Properties | ChemMedChem | 2006 | 223 |
| 22 | Superparamagnetic Iron Oxide Nanoparticle–Aptamer Bioconjugates for Combined Prostate Cancer Imaging and Therapy | ChemMedChem | 2008 | 222 |
| 23 | Identification and Optimization of the First Highly Selective GLUT1 Inhibitor BAY‐876 | ChemMedChem | 2016 | 220 |
| 24 | Long Noncoding RNAs: Emerging Stars in Gene Regulation, Epigenetics and Human Disease | ChemMedChem | 2014 | 214 |
| 25 | Ferrocene Conjugates of Chloroquine and other Antimalarials: the Development of Ferroquine, a New Antimalarial | ChemMedChem | 2008 | 209 |
| 26 | Further Evidence of the Anti‐inflammatory Effects of Silver Nanoparticles | ChemMedChem | 2009 | 206 |
| 27 | Discovery of BAY 94‐8862: A Nonsteroidal Antagonist of the Mineralocorticoid Receptor for the Treatment of Cardiorenal Diseases | ChemMedChem | 2012 | 203 |
| 28 | Co-Delivery of Hydrophobic and Hydrophilic Drugs from Nanoparticle–Aptamer Bioconjugates | ChemMedChem | 2007 | 202 |
| 29 | Molecular Recognition of Small‐Cell Lung Cancer Cells Using Aptamers | ChemMedChem | 2008 | 201 |
| 30 | Cyclobutanes in Small‐Molecule Drug Candidates | ChemMedChem | 2022 | 196 |
| 31 | The Role of the Phosphorus Atom in Drug Design | ChemMedChem | 2019 | 194 |
| 32 | Structural Basis for the Exceptional in vivo Efficacy of Bisphosphonate Drugs | ChemMedChem | 2006 | 189 |
| 33 | Covalent Inhibition in Drug Discovery | ChemMedChem | 2019 | 187 |
| 34 | Malaria Chemotherapeutics Part I: History of Antimalarial Drug Development, Currently Used Therapeutics, and Drugs in Clinical Development | ChemMedChem | 2007 | 174 |
| 35 | A PEG-Based Biocompatible Block Catiomer with High Buffering Capacity for the Construction of Polyplex Micelles Showing Efficient Gene Transfer toward Primary Cells | ChemMedChem | 2006 | 172 |
| 36 | Aryloxy Phosphoramidate Triesters: a Technology for Delivering Monophosphorylated Nucleosides and Sugars into Cells | ChemMedChem | 2009 | 170 |
| 37 | Evaluation of tert‐Butyl Isosteres: Case Studies of Physicochemical and Pharmacokinetic Properties, Efficacies, and Activities | ChemMedChem | 2015 | 168 |
| 38 | Characterization of Solid Counterfeit Drug Samples by Desorption Electrospray Ionization and Direct-analysis-in-real-time Coupled to Time-of-flight Mass Spectrometry | ChemMedChem | 2006 | 165 |
| 39 | The Tunable Functionality of α,β‐Unsaturated Carbonyl Compounds Enables Their Differential Application in Biological Systems | ChemMedChem | 2010 | 164 |
| 40 | Discovery of MK‐8742: An HCV NS5A Inhibitor with Broad Genotype Activity | ChemMedChem | 2013 | 164 |
| 41 | Towards an Integrated Description of Hydrogen Bonding and Dehydration: Decreasing False Positives in Virtual Screening with the HYDE Scoring Function | ChemMedChem | 2008 | 163 |
| 42 | Click Chemistry and Medicinal Chemistry: A Case of “Cyclo‐Addiction” | ChemMedChem | 2008 | 160 |
| 43 | Improving Nonspecific Binding and Solubility: Bicycloalkyl Groups and Cubanes as para‐Phenyl Bioisosteres | ChemMedChem | 2017 | 159 |
| 44 | Novel Pieces for the Emerging Picture of Sulfoximines in Drug Discovery: Synthesis and Evaluation of Sulfoximine Analogues of Marketed Drugs and Advanced Clinical Candidates | ChemMedChem | 2017 | 158 |
| 45 | Exploring Chemical Modifications for siRNA Therapeutics: A Structural and Functional Outlook | ChemMedChem | 2010 | 157 |
| 46 | Antibody Conjugation of a Chimeric BET Degrader Enables in vivo Activity | ChemMedChem | 2020 | 156 |
| 47 | Structure–Activity Studies on Suramin Analogues as Inhibitors of NAD+‐Dependent Histone Deacetylases (Sirtuins) | ChemMedChem | 2007 | 154 |
| 48 | PET Imaging of CXCR4 Receptors in Cancer by a New Optimized Ligand | ChemMedChem | 2011 | 152 |
| 49 | Galloflavin (CAS 568‐80‐9): A Novel Inhibitor of Lactate Dehydrogenase | ChemMedChem | 2012 | 152 |
| 50 | Identification of Atuveciclib (BAY 1143572), the First Highly Selective, Clinical PTEFb/CDK9 Inhibitor for the Treatment of Cancer | ChemMedChem | 2017 | 152 |
